Curriculum Vitae

Joyce Ann O'Shaughnessy, M.D.

Home Address: 4137 Amherst Avenue

Dallas, Texas 75225 (214) 361-0916

Business Address: Texas Oncology and US Oncology

3410 Worth Street, Ste 400

Dallas, Texas 75246 (214) 370-1795

Education:

1978 – 1982 Yale University Medical School

M.D., 1982 Thesis Title: Influence of Cytotoxic Drugs and L1210 Suspension Culture Density on de novo Purine

Synthesis, 1982

1974 – 1978 Holy Cross College

B.A. Biology, 1978

Post-Graduate Training:

1985 – 1988 Fellowship, National Cancer Institute

Medical Oncology

1982 – 1985 Internship and Residency

Internal Medicine

Massachusetts General Hospital

Board Certification:

1987 Medical Oncology Board Certification

1985 Diplomate, American Board of Internal Medicine

1982 Diplomate, National Board of Medical Examiners

<u>Licensure</u>: Texas Medical License K3366



Chronology of Employment:

2010 - Present	Medical Director, US Oncology Research
2000 - Present	Co-Chair, Breast Cancer Research, US Oncology
2000 – 2009	Director, Cancer Prevention Program Baylor - Charles A. Sammons Cancer Center, Dallas, TX
1997 - Present	Medical Oncologist, Texas Oncology
1995 – 1997	Kentuckiana Medical Oncology Associates Louisville, KY
1990 – 1995	Senior Investigator Medical Breast Cancer Section Division of Cancer Treatment National Cancer Institute
1988 – 1990	Special Assistant to the Director National Cancer Institute
1987 – 1988	Senior Investigator Biologics Evaluation Section Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute
1986 – 1987	Post-doctoral Fellow Laboratory of Tumor Virus Biology National Cancer Institute
1980 – 1982	Graduate Student Laboratory of Cancer Pharmacology Yale Medical School
1977 – 1978	Instructor in Electron Microscopy Worcester Foundation for Experimental Biology
1976 – 1978	Research Assistant Worcester Foundation for Experimental Biology
Appointments:	
2009 - Present	Celebrating Women Endowed Chair in Breast Cancer Research, Baylor University Medical Center, Dallas, TX
2009 - 2011	Program Committee, ASCO Breast Cancer Symposium
2004 – 2007	Member, ASCO Nominating Committee
2003 – 2007	Member, AACR Task Force on Cancer Prevention



2003 - Present	Program Director, The School of Breast Oncology
2003- Present	Deputy Editor, Clinical Breast Cancer
2002 – 2007	Member, AACR Clinical Research Advisory Committee
2000	Co-Chair, AACR Chemoprevention Annual Meeting Symposium
1999 – 2002	Co-Chair, AACR-FDA Intraepithelial Neoplasia Task Force
1999 – 2007	Member, Baylor University Institutional Review Board
1998 – 2007	Medical Advisor Susan G. Komen Foundation
1997 – 2005	Chair, Clinical Research Steering Committee, US Oncology
1997 – 1998	NCI Breast Cancer Progress Review Group
1997 – 2003	Clinical Associate Professor of Medicine UT Southwestern Medical School
1997 – Present	Member, Scientific Advisory Board US Oncology
1996 – 1997	Member, Jewish Hospital Ethics Committee Louisville, KY
1996 – 1997	Clinical Associate Professor University of Louisville School of Medicine
1996	NCI Breast Cancer Fine Needle Aspirate Working Group
1995 – 1997	Member, Breast Cancer Prevention and Treatment Committees, Alliant Health Care System, Louisville, KY
1995 - Present	NCI PDQ Protocol External Advisory Board
1995 – 1996 and 2002	ASCO Breast Cancer Program Committee
1994 – 1995	Member, Source Evaluation Group for RFP's for Chemoprevention Clinical Trials, NIH
1994	Member, Scientific Advisory Board California Breast Cancer Research Program
1993 – 1995	Member, NCI Institutional Review Board
1993 – 1995	Chair, NCI Division of Cancer Treatment's Women's Subcommittee on Clinical Research



1993 – 1995	Division of Cancer Treatment Representative to NIH Breast Cancer Working Group
1992 – 1995	Division of Cancer Treatment Representative to NCI Chemoprevention Working Group
1992 – 1993	National Cancer Institute Representative to the District of Columbia Cancer Consortium
1992	Clinical Tenure granted at NCI, NIH
1991	NCI Representative to the AMA Women's Health Campaign
1991 – 1995	Scientific Advisory Board, Cancer Research Foundation of America
1990 – 1995	National Cancer Institute Spokesperson on Breast Cancer
1990 – 1995	Medical Advisor to My Image After Breast Cancer Advocacy Group
1990	Member, American Joint Commission on Cancer, Working Group on Prognostic Factors in Breast Cancer
1989 – 1991	Coordinator for the FDA/NCI Subcommittee on Cancer Drug Approval Endpoints
1989 – 1990	Coordinator for the FDA/NCI Drug Development Working Group
1989	Coordinator of the NCI/FDA Medical Oncology Fellowship Program
1988 – 1990	Executive Secretary for the National Cancer Institute Advisory Board AIDS Subcommittee
1988 – 1990	NCI Liaison to the NIH AIDS Advisory Committee
1988 – 1996	Holy Cross College Board of Trustees
1980 – 1982	Yale Medical School Council
Honors:	
2003	Holy Cross College Santae Crucis Award (Distinguished Alumni Award)
1991	Public Health Service Special Service Award for Development of the Consensus Statement on Cancer Drug Approval Endpoints
1982	Yale Medical School, Francis Parker Award (Faculty Choice for Most Promising Clinician)



1982 Yale Medical School, Cum Laude

1982 Medical Honor Society, Alpha Omega Alpha

1978 Jesuit Honor Society, Alpha Sigma Nu

Holy Cross College, Summa Cum Laude

1978 Holy Cross Fenwick Scholar (Senior Year of

Independent Research at Holy Cross College)

Thesis Title: Ultrastructural microscopic analysis of human

and murine leukemia cells

1977 Holy Cross College, Phi Beta Kappa

Professional Societies:

American Association for Cancer Research American Society of Clinical Oncology American Medical Women's Association

Women in Cancer Research Texas Medical Association American College of Physicians American Medical Association

Ad Hoc Editorial Reviewer:

Breast Cancer Research and Treatment

Journal of the National Cancer Institute

Journal of Clinical Oncology New England Journal of Medicine

Oncology Cancer Breast

The Oncologist Annals of Oncology

PUBLICATIONS

- 1. Cadman E, Benz C, Heimer R, and O'Shaughnessy J. *The effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity*. Biochemical Pharmacology 30:2469-2472, 1981.
- 2. Cadman E, Benz C, Heimer R, and O'Shaughnessy J. *The modulation of 5-fluorouracil metabolism by inhibitors of de novo purine synthesis: in nucleosides and cancer therapy.* H.M.N. Tattersall and R.M. Fox, eds., Academic Press, 1981.
- 3. Bolen J, DeSeau V, O'Shaughnessy J, and Amini S. *Analysis of middle tumor antigen and pp60 c-src interactions in polyoma virus-transformed rat cells.* Virology 61:3299,1987.
- 4. O'Shaughnessy J, DeSeau V, Amini S, Rosen N, and Bolen J. *Analysis of the c-src gene product structure, abundance and protein kinase activity in human neuroblastoma and glioblastoma cells.* Oncogene Research 2:1, 1987.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

